| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total research and development | 2,403,363 | - |
| Total selling, general and administrative | 3,469,842 | - |
| Interest income | 176,536 | - |
| Net loss | -5,696,669 | -4,004,680 |
| Stock-based compensation | 114,263 | 76,422 |
| Prepaid expenses and other current assets | 34,965 | -212,732 |
| Accounts payable | -304,089 | -356,816 |
| Accrued and other current liabilities | -506,902 | -552,205 |
| Total adjustments to reconcile net loss to net cash used in operations | -731,693 | -619,867 |
| Net cash used in operating activities | -6,428,362 | -4,624,547 |
| Proceeds from issuance of common stock and warrants, net of issuance costs | 7,980,804 | 7,993,425 |
| Payment of prior period issuance costs | 50,495 | 50,495 |
| Issuance costs paid setting up atm agreement | - | 0 |
| Proceeds from exercise of pre-funded warrants | 977 | 977 |
| Payment for fractional shares in reverse stock split | -367 | 0 |
| Net cash provided by financing activities | 7,930,919 | 7,943,907 |
| Net increase (decrease) in cash and cash equivalents | 1,502,557 | 3,319,360 |
| Cash and cash equivalents at beginning of period | 3,161,570 | - |
| Cash and cash equivalents at end of period | 4,664,127 | - |
Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc. (DRMA)